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Background: Prosthetic implants used in total hip replacements Results: Small-head cemented metal-on-polyethylene implants were
(THR) have a range of bearing surface combinations (metal-on-
polyethylene, ceramic-on-polyethylene, ceramic-on-ceramic, and
metal-on-metal), head sizes (small [<36 mm in diameter] and large
[36 mm in diameter]), and fixation techniques (cemented, unce-
mented, hybrid, and reverse hybrid). These can influence prosthesis
survival, patients’ quality of life, and healthcare costs. Objectives:
To compare the lifetime cost-effectiveness of implants for patients
of different age and sex profiles. Methods: We developed a Markov
model to compare the cost-effectiveness of various implants against
small-head cemented metal-on-polyethylene implants. The probability
that patients required 1 or more revision surgeries was estimated from
analyses of more than 1 million patients in the UK and Swedish hip
joint registries, for men and women younger than 55, 55 to 64, 65 to 74,
75 to 84, and 85 years and older. Implant and healthcare costs were
estimated from local procurement prices, national tariffs, and the
literature. Quality-adjusted life-years were calculated using published
utility estimates for patients undergoing THR in the United Kingdom.* Address correspondence to: Elsa M.R. Marques, PhD, Musculoskele
Bristol Medical School, University of Bristol, Learning & Research Bld
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https://doi.org/10.1016/j.jval.2018.08.013the most cost-effective for men and women older than 65 years. These
findings were robust to sensitivity analyses. Small-head cemented
ceramic-on-polyethylene implants weremost cost-effective inmen and
women younger than 65 years, but these results were more uncertain.
Conclusions: The older the patient group, the more likely that the
cheapest implants, small-head cemented metal-on-polyethylene im-
plants, were cost-effective. We found no evidence that uncemented,
hybrid, or reverse hybrid implants were the most cost-effective option
for any patient group. Our findings can influence clinical practice and
procurement decisions for healthcare payers worldwide.
Keywords: combinations, cost-effectiveness, prosthetic hip implant,
total hip replacement
Copyright© 2019, ISPOReThe Professional Society for Health Economics
andOutcomesResearch. PublishedbyElsevier Inc.This is anopenaccess
article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Total hip replacement (THR) is one of the most successful sur-
geries performed worldwide,1 with 87 733 primary THRs per-
formed in England and Wales in 2016.2 In Sweden, there were 16
609 surgeries performed in 2015, which was 329 per 100 000 in-
habitants aged 40 years and older,3 and a further 8 402 in Norway
and 44 710 in Australia.4 In the United States, an estimated 2.5
million people are living with a hip replacement.5 The firsteffective hip implants were developed in the 1950s, with a small
metal head that articulates with a polyethylene cup fixed with
cement. They are the cheapest and most prevalent type of hip
implant, with a long track record of use worldwide.2-4,6 The
polyethylene component wears with increased physical activity
and load, resulting in loosening and bone loss over time, which is
of more consequence in younger and more active patients
because implant failure requires further surgery to revise and
replace the prosthetic hip implant.1 Newer polyethylenes,tal Research Unit, Department of Translational Health Sciences,
g (Level 1), Southmead Hospital, Bristol BS10 5NB, UK.
l Society for Health Economics and Outcomes Research. Published
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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different fixation methods have been developed to improve long-
term patient outcomes,1 but at potentially much higher costs.
Recent observational evidence found that newer metal-on-
metal implants failed more often than traditional metal-on-
polyethylene implants, which caused much concern to patients
and clinicians.7 Some studies suggested that ceramic-on-ceramic
or ceramic-on-polyethylene prostheses, which can cost 4 times
more than metal-on-polyethylene implants, performed better in
young and active patients, and so their use is increasing in many
countries.2-4,8 Given the range of implant combinations currently
available at widely different prices, and the rising volume of THR
procedures performed worldwide, it is important to consider the
cost-effectiveness of prosthetic implants for different patient
groups undergoing THR surgery.
In this article, we compared the lifetime cost-effectiveness of
hip implant combinations for men and women of different age
profiles in the United Kingdom. Previous models have examined
the cost-effectiveness of prosthetic implants, but may have used
simpler assumptions, such as assuming constant risks of revi-
sion after surgery,9 without reliable long-term estimates,9-11 or
were too narrow in scope, comparing few or just 2 implants9-12 or
only 1 or more implant material.13-15 Previous models either
grouped patients13,16,17 or examined a small subset of different
age and sex profiles.10,11 Our work exceeds previous analyses by
(1) assessing complete implant combinations that form the
constructs currently in clinical use, (2) incorporating high-
quality real-world evidence on implant survival and allowing
the risk of revision to vary over time, and (3) focusing on a wide
array of patient subgroups. Our findings provide evidence to
inform the decisions of patients, surgeons, and healthcare
commissioners worldwide.Methods
Prosthetic Implant Combinations for Analysis
There were 24 implant combinations compared in this analysis,
defined by bearing surface combination, fixation technique,
and femoral head size (see Appendix 1 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2018.08.013).18
Bearing surface combinations included metal-on-
polyethylene, metal-on-metal, ceramic-on-polyethylene, and
ceramic-on-ceramic implants; surgical fixation techniquesFigure 1 – Markov model structuredbase-case analysis. *Patien
revisions but return to the same state thereafter. THR indicateswere cemented, uncemented, hybrid, and reverse hybrid; and
femoral heads were considered small if less than 36 mm in
diameter and large if 36 mm or more in diameter. We consid-
ered only implants in current regular clinical practice; implants
rarely used, namely, ceramic-on-metal and cemented ceramic-
on-ceramic and metal-on-metal, were excluded. The “reference
implant” combination for analysis was the small-head (<36
mm) cemented metal-on-polyethylene implant, the most
commonly used implant combination in the United Kingdom,2
as elsewhere.3,8
Model Development and Structure
To develop our model, we consulted with hip surgeons and pa-
tients to make realistic assumptions about the risk of revision
over time and to identify outcomes that might be relevant for
analysis. We searched the MEDLINE and Embase databases on
OvidSP, and the National Health Service (NHS) economic evalua-
tion database for models used in previous economic evaluations,
as detailed in Appendix 2 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2018.08.013; an overview of these
studies is also provided in this appendix.
We developed a Markov model with a lifetime time horizon
and a 1-year cycle length (Fig. 1), as in previous economic
models.13,15,19 Unlike previous models, the hazard of first revision
was assumed to vary between 3 time periods after primary THR
surgery (“early,” up to 2 years; “middle,” 2-10 years; and “late,” 10
years or more) but remain constant within each period. This
assumption was based on clinical opinion and observation of
implant survivorship data from successive annual reports of the
National Joint Registry (NJR) for England, Wales, Northern Ireland,
and the Isle of Man,20 which showed that the hazard of first
revision after primary THR was high within the initial period after
surgery, low in the medium term, and rising in the longer term.
Failure in the early period is predominantly from dislocation,
fracture (from intraoperative events), and infection; the middle
period from a wide range of causes; and the late period predom-
inantly from aseptic loosening and wear. Fixation and bearing
surface materials have an effect on which implants fail in each of
these time periods. For example, uncemented implants are at a
higher risk of both early postoperative fracture and subsidence.
After consultation with a range of clinicians and methodologists
and analysis of the NJR and the Swedish Hip Arthroplasty Register
(SHAR), we set our cutoffs at 0 to 2 years for early first revision, 2 to
10 years for middle first revision, and 10 ormore years for late firstts in postesecond revision state can experience further
total hip replacement.
V A L U E I N H E A L T H 2 2 ( 2 0 1 9 ) 3 0 3 e3 1 2 305revision (and considered sensitivity around these cutoffs, as
further detailed). Clinical opinion also suggested that hazard of a
second revision was higher for patients who had a first revision
sooner after primary THR, which was also confirmed by NJR
data.2,21 We separately tracked cohorts with early, middle, and
late first revisions using Markov tunnel states. Patients who had 2
or more revisions were tracked in a single “postesecond revision”
health state. Patients could die at any stage, because of post-
operative mortality or all-cause mortality.
Data
Evidence sources for the model inputs are presented in Table 1
and described herein.
Estimating the hazard of revision surgery
We conducted a network meta-analysis of randomized controlled
trials (RCTs) comparing revision rates between implant combi-
nations, but because of the small size of most studies, limited
follow-up periods, and poor reporting, there was insufficient evi-
dence on the hazard of revision to inform ourmodel.22We instead
used individual-patient observational data from the NJR, the
largest national joint replacement cohort with 796 636 records of
primary THR surgeries since 2003/2004.2 The number of primary
and revision surgeries and length of follow-up provided by the NJR
are presented in Table 2. For longer term estimates (beyond NJR
follow-up), we analyzed data from the SHAR, which has up to 25
years of follow-up on 359 579 primary THRs.3
In both registries, we defined revision surgery as the removal
of failing implants and/or insertion of new components (see
Appendix 3a in Supplemental Materials found at https://doi.org/
10.1016/j.jval.2018.08.013). The registries provided information
on time to first revision, by age bracket (younger than 55, 55-64, 65-
74, 75-84, and 85 years and older) and sex. To reflect the
assumption that risk of revision varies with time from primary
surgery, we estimated the hazard of first revision for 3 different
time periods (early, middle, and late). We used a piecewise con-
stant hazard model to estimate the baseline hazard of revision for
patients using the reference implant for each period, and esti-
mated hazard ratios of revision for all other implants, stratified by
age and sex (see Appendix 3b in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2018.08.013). This involved fitting
separate functions to each of the 10 age and sex subgroups, with
hazard ratios estimated for each of the 23 implants relative to the
reference implant (small-head cemented metal-on-polythene
implant). By assuming a piecewise constant hazard model with
constant hazard ratios over the 3 time periods, it allowed certain
implants, such as ceramic-on-polyethylene, to have a greater
impact on late rather than early revisions (further details are
provided in Appendix 3b in Supplemental Materials). Because our
focus was on UK policy, we used the NJR data for the short- and
medium-term periods (early andmiddle), where reliable estimates
were observed. We calibrated estimates from SHAR to the NJR
population where sufficient evidence was available from both (see
Appendix 3c in Supplemental Materials found at https://doi.org/1
0.1016/j.jval.2018.08.013). We then used these calibrated SHAR
estimates to predict the longer termNJR estimates, and the shorter
term estimates where NJR estimates were unreliable. The esti-
mated probabilities are presented in Appendix 3d in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2018.08.013.
We estimated the baseline hazard of second revision using
NJR data for patients who had an early revision, and hazard ratios
for patients who had middle and late revisions. Because of
limited data on the hazard of second revision, we assumed the
same rate across implant types and over time. A common hazard
of subsequent revision (third or higher) was also estimated
(Table 1).Mortality
We assumed postoperative mortality (within 90 days of surgery).
We assumed mortality rates were constant between implant
combinations, but varied by age and sex, as per clinical advice.
The NJR data were used to estimate 90-day mortality for primary
THR, by age and sex (Table 1). The data on mortality after revision
surgeries by age and sex were limited. To estimate postoperative
mortality after revision surgery, we used a Bayesian multipa-
rameter evidence synthesis model using aggregated data on
revision surgery and information on primary THR (see Appendix 4
in Supplemental Materials found at https://doi.org/10.1016/j.jval.2
018.08.013).
We also applied all-cause mortality rates, stratified by age and
sex, to all patients using UK data from the Office for National
Statistics.23
Cost estimates
The model considered costs from the health and social care payer
perspectives. We included the cost of the implant used in primary
THR, but excluded the cost of primary THR surgery because we
assumed these costs were common across implants; this
assumption was tested in sensitivity analysis because surgery
costs may vary by fixation method, for example. We excluded the
cost of adverse events, such as stroke or heart attack, because
there is no good-quality evidence to suggest that the risk of these
medical complications vary significantly by implant, and mortal-
ity from these complications does not relate to implant choice.24
Implant prices were obtained from the North Bristol NHS Trust
and were comparable with average prices paid nationally.25
We included the cost of revision surgery and follow-up care
after revision surgery. On the basis of clinical opinion, we
weighted the published Department of Health national reference
costs for revision surgery to estimate the average cost of revision
surgery, which reflected complications and comorbidities, average
length of stay, and average cost per excess bed day.26 We assumed
the same cost of revision for first and subsequent revision sur-
geries. We included published ambulatory care costs for the first
12 months postsurgery,27 inflated to 2015/2016 prices using the
Hospital and Community Health Services index (Table 1).28
All unit costs were expressed in sterling (£) and valued at 2015/
2016 prices.
Quality-of-life estimates
We obtained quality-of-life data, or health utilities, from the UK
Patient-Reported OutcomeMeasures (PROMs) data set for patients
who had a THR in 2010/2011.29 The PROMs data set recorded 3-
level EuroQol 5-dimensional questionnaire data at 6 months
after primary and revision surgeries for 32 577 patients older than
40 years, with complete data. We assumed the same utilities after
first and subsequent revisions. Utilities were not stratified by
implant type because improvements in patients’ outcomes at 6
months postsurgery are comparable across implant types.30 Util-
ities were stratified by age and sex for primary THR, and sex only
for revision surgery (Table 1). The health utilities were combined
with survival to estimate quality-adjusted life-years (QALYs).
Cost-Effectiveness Analysis
Base-case analysis
The base-case analysis compared the lifetime cost-effectiveness of
24 implant combinations formen andwomenyounger than 55, 55 to
64, 65 to 74, 75 to 84, and 85 years and older in the United Kingdom.
Estimated costs and QALYs were discounted at 3.5% per annum, as
per the National Institute for Health and Care Excellence guide-
lines.31 We calculated expected costs and QALYs per 1000 patients
using a probabilistic analysis,which reflectedparameter uncertainty
Table 1 – Model input parameters.
Estimate SE Distribution Source
Revision risks
Probability of first revision Appendix 3d Appendix 3d Normal NJR/SHAR
Log hazard rates of second revision from
Early first revision 3.446 0.031 Normal NJR
Middle first revision 0.181 0.045 Normal NJR
Late first revision 0.256 0.290 Normal NJR
Log hazard rates of third revision
3 or more revisions 2.849 0.053 Normal NJR
Mortality
Log hazard rates of 90-d mortality after
primary THR
Men
<55 y 5.019 0.115 Normal NJR
55-64 y 4.691 0.075 Normal NJR
65-74 y 4.069 0.047 Normal NJR
75-84 y 3.156 0.037 Normal NJR
>85 y 2.041 0.056 Normal NJR
Women
<55 y 4.922 0.110 Normal NJR
55-64 y 4.983 0.079 Normal NJR
65-74 y 4.559 0.049 Normal NJR
75-84 y 3.664 0.035 Normal NJR
>85 y 2.596 0.046 Normal NJR
Log hazard rates of 90-d mortality after
first revision*
Men
<55 y 4.296 0.135 Normal NJR
55-64 y 3.967 0.103 Normal NJR
65-74 y 3.346 0.084 Normal NJR
75-84 y 2.433 0.079 Normal NJR
>85 y 1.317 0.089 Normal NJR
Women
<55 y 4.199 0.129 Normal NJR
55-64 y 4.259 0.106 Normal NJR
65-74 y 3.835 0.086 Normal NJR
75-84 y 2.940 0.079 Normal NJR
>85 y 1.872 0.085 Normal NJR
Log hazard rates of 90-d mortality after
second or subsequent revision*
Men
<55 y 4.306 0.252 Normal NJR
55-64 y 3.977 0.236 Normal NJR
65-74 y 3.356 0.228 Normal NJR
75-84 y 2.443 0.226 Normal NJR
>85 y 1.327 0.231 Normal NJR
Women
<55 y 4.209 0.250 Normal NJR
55-64 y 4.269 0.237 Normal NJR
65-74 y 3.846 0.229 Normal NJR
75-84 y 2.950 0.227 Normal NJR
>85 y 1.882 0.229 Normal NJR
Costs
Implant costsy
MoP cemented £756.00 NA Fixed North Bristol Trust
MoP uncemented £2047.00 NA Fixed North Bristol Trust
MoP hybrid £1315.00 NA Fixed North Bristol Trust
MoP reverse hybrid £1107.00 NA Fixed North Bristol Trust
MoM uncemented £1924.00 NA Fixed North Bristol Trust
MoM hybrid £1662.00 NA Fixed North Bristol Trust
CoP cemented £1038.00 NA Fixed North Bristol Trust
CoP uncemented £2386.00 NA Fixed North Bristol Trust
CoP hybrid £1597.00 NA Fixed North Bristol Trust
continued on next page
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Table 1 – continued
Estimate SE Distribution Source
CoP reverse hybrid £1446.00 NA Fixed North Bristol Trust
CoC uncemented £2262.00 NA Fixed North Bristol Trust
CoC hybrid £1848.00 NA Fixed North Bristol Trust
Revision costs
Revision THRz £8595.83 £1524.29 Normal Department of Health26
12-mo ambulatory care costs after
revision surgeryx
Outpatient £305.18 £29.03 Normal Edlin et al27
Primary/community £54.18 £9.26 Normal Edlin et al27
Aids and adaptations £23.22 £5.53 Normal Edlin et al27
Medication £26.54 £5.67 Normal Edlin et al27
Total resource use costs £409.12
Quality of life
UtilitiesdPROMsjj
Primary THR
Men
<55 y 0.736 0.018 Normal UK Patient-Reported Outcome Measures29
55-64 y 0.767 0.007 Normal UK Patient-Reported Outcome Measures29
65-74 y 0.762 0.004 Normal UK Patient-Reported Outcome Measures29
75-84 y 0.790 0.003 Normal UK Patient-Reported Outcome Measures29
>85 y 0.790 0.007 Normal UK Patient-Reported Outcome Measures29
Women
<55 y 0.720 0.013 Normal UK Patient-Reported Outcome Measures29
55-64 y 0.742 0.006 Normal UK Patient-Reported Outcome Measures29
65-74 y 0.769 0.003 Normal UK Patient-Reported Outcome Measures29
75-84 y 0.747 0.003 Normal UK Patient-Reported Outcome Measures29
85 y 0.710 0.005 Normal UK Patient-Reported Outcome Measures29
Revision surgery
Men 0.575 0.009 Normal UK Patient-Reported Outcome Measures29
Women 0.553 0.007 Normal UK Patient-Reported Outcome Measures29
CC, complications and comorbidities; CoC indicates ceramic-on-ceramic; CoP, ceramic-on-polyethylene; HRG, Healthcare Resource Group;
MoM, metal-on-metal; MoP, metal-on-polyethylene; NA, not applicable; NJR, National Joint Registry; PROMs, patient-reported outcome mea-
sures; SE, standard error.
* Bayesian estimate (see Appendix 4 in Supplemental Materials).
y Implant prices did not vary by femoral head size.
z The current HRG v.4 2014-2015 reference costs in the United Kingdom were used to estimate the cost of revision surgery, which reflects the
average length of stay and average cost per excess bed day. HRGs describe varying levels of complications and comorbidities, which allowed us
to model complete costs using a weighted average cost. We followed clinical opinion to assign a representative HRG code to revision surgery:
HN81A-HN81E (complex, hip or knee procedures for nontrauma, with complications and comorbidities score 0-9þ). We used information on
the interquartile range to estimate the SE, assuming a normal distribution.
x We inflated the estimates to current prices (2015/2016) using the Hospital and Community Health Services index.
k Assuming studied age bands.
V A L U E I N H E A L T H 2 2 ( 2 0 1 9 ) 3 0 3 e3 1 2 307in the sampled distributions (Table 1). Using Microsoft Excel
software,32 we simulated 10 000 iterations. We estimated cost-
effectiveness using the mean incremental net monetary benefit
(INMB) statistic for each implant compared with the reference
implant, at National Institute for Health and Care Excellence’s lower
willingness-to-pay threshold of £20 000 per QALY gained.31 The
implant with the highest mean INMB reflected the most cost-
effective implant in each subgroup. We illustrated the probability
that implants weremost cost-effective at varyingwillingness-to-pay
thresholds using cost-effectiveness acceptability curves.
Sensitivity analyses
Our sensitivity analyses assessed the robustness of the results to
changes in key parameters and assumptions.
In a sensitivity analysis scenario,weharmonized implant prices
by setting them as equal (£0) to assess the extent that cost-
effectiveness findings might be influenced by implant prices
alone. Uncemented implants typically cost £1300 more than their
cemented counterparts (Table 1), and clinical opinion suggests thatsurgery time is shorter, saving approximately 20minutes of theater
time. Theater time has been valued at £15 per minute in a previous
study.33 Setting cemented and uncemented implant costs as equal
is equivalent to saving, on average, 90 minutes of theater time at
£15 per minute,33 or 20 minutes at a higher cost of £65 per minute.
There is no strong evidence for our choice of time periods to
define early, middle, and late periods for revision risks. We
therefore assessed sensitivity to this key structural assumption by
adjusting the time periods. In this scenario, we assumed 0 to 5
years for early first revision, 5 to 10 years for middle first revision,
and 10 or more years for late first revision.Results
Base-Case Findings
Table 3 ranks the top implant combinations by their expected
mean INMB for each age and sex subgroup. Complete base-case
Table 2 – Number of primary and revision surgeries and length of follow-up provided by the National Joint Registry.
Implant Number of
primaries
Number of
revisions
Date of earliest
primary
Date of latest
primary
Length of
follow-up (y)
MoP Cem S 243 292 3 951 April 1, 2003 December 1, 2015 12.7
MoP Cem L 3 742 52 December 2, 2003 December 1, 2015 12.0
CoP Cem S 27 747 324 April 1, 2003 December 1, 2015 12.7
CoP Cem L 797 15 January 12, 2005 December 1, 2015 10.9
MoP Uncem S 94 709 2 135 April 1, 2003 December 1, 2015 12.7
MoP Uncem L 23 954 487 September 18, 2003 December 1, 2015 12.2
MoM Uncem S 2 075 159 April 1, 2003 January 11, 2013 9.8
MoM Uncem L 26 542 3 687 April 8, 2003 November 7, 2013 10.6
CoP Uncem S 39 936 746 April 1, 2003 December 1, 2015 12.7
CoP Uncem L 13 147 198 March 14, 2005 December 1, 2015 10.7
CoC Uncem S 39 822 1 007 April 2, 2003 December 1, 2015 12.7
CoC Uncem L 64 021 1 221 April 9, 2003 December 1, 2015 12.7
MoP Hyb S 70 002 1 254 April 1, 2003 December 1, 2015 12.7
MoP Hyb L 21 046 303 April 7, 2003 December 1, 2015 12.7
MoM Hyb S 509 42 April 2, 2003 February 27, 2012 8.9
MoM Hyb L 1 637 227 April 8, 2003 August 28, 2012 9.4
CoP Hyb S 17 419 192 April 2, 2003 December 1, 2015 12.7
CoP Hyb L 10 105 97 January 22, 2005 December 1, 2015 10.9
CoC Hyb S 15 908 244 April 3, 2003 December 1, 2015 12.7
CoC Hyb L 5 547 94 June 20, 2003 December 1, 2015 12.5
MoP RevHyb S 13 174 223 April 2, 2003 December 1, 2015 12.7
MoP RevHyb L 239 7 January 13, 2005 December 1, 2015 10.9
CoP RevHyb S 6 086 98 April 1, 2003 December 1, 2015 12.7
CoP RevHyb L 201 5 September 21, 2007 December 1, 2015 8.2
Source: National Joint Registry (unpublished data, 2016).
Cem indicates cemented; CoC, ceramic-on-ceramic; CoP, ceramic-on-polyethylene; Hyb, hybrid; L, large; MoM,metal-on-metal; MoP, metal-on-
polyethylene; RevHyb, reverse hybrid; S, small; Uncem, uncemented.
V A L U E I N H E A L T H 2 2 ( 2 0 1 9 ) 3 0 3 e3 1 2308findings are provided in Appendix 5, and the cost-effectiveness
acceptability curves are presented in Appendix 6 in Supple-
mental Materials found at https://doi.org/10.1016/j.jval.2018.08.
013. Small-head cemented ceramic-on-polyethylene implant
had the highest expected mean INMB for men and women
younger than 65 years (Table 3). This result was uncertain and
driven by imprecise revision rate estimates, with low likelihood
of being the most cost-effective implant. For adults aged 55 to 64
years, for example, the mean INMB was £514 (95% confidence
interval [CI] £313 to £1807) for men and £104 (95% CI £729 to
£625) for women; the probability that small-head cemented
ceramic-on-polyethylene implant was the most cost-effective
choice in these subgroups was less than 50%. Despite higher
implant prices, the lower risk of revision in these patient groups
(see Appendix 3d in Supplemental Materials) led to lower average
lifetime costs and higher QALY gains compared with the refer-
ence implant. Uncemented, hybrid, reverse hybrid, and other
bearing surface combinations performed poorly in these age
groups, partly because of higher implant costs, but also because
of poorer revision rates.
In older age categories, the small-head cemented metal-on-
polyethylene implant combination (reference implant) consis-
tently displayed lower implant and lifetime costs, low revision
rates, and the same or higher QALY gains than all other implant
combinations. The probability that the reference implant was the
most cost-effective implant combination was high, with more
than 80% probability of being the most cost-effective choice for
adults older than 75 years. All alternative implant combinations,
including implants with large head sizes, performed poorly, with
negative mean INMBs (due to higher implant costs) or higher
revision rates. Across all subgroups, large-head implant combi-
nations were not cost-effective.Sensitivity Analysis Findings
When implant prices were harmonized, allowing us to assess the
effect of implant prices and surgery costs on cost-effectiveness
findings, differences in lifetime costs between first- and second-
best implants were often minor. As such, all findings were more
uncertain, and the probability that any implant was themost cost-
effective implant was much lower than the base-case analysis
(Table 4; see Appendix 5 in Supplemental Materials). Hybrid and
uncemented ceramic implants became more cost-effective, rising
to the top 3 positions compared with the base-case analysis.
Nevertheless, harmonizing implant prices did not affect the base-
case findings for men, although in women aged 55 to 64 years,
small-head hybrid ceramic-on-ceramic implant combination was
now preferred to small-head cemented ceramic-on-polyethylene
implant combination (mean INMB ¼ £478 [95% CI £1006 to
£1131]). The uncertainty observed in the newer implant types
suggested that even though they were designed to reduce revision
rates,34 this has not been evidenced in registry data.
The base-case findings were robust to the change in the time
periods for revision risks after primary THR (see Appendix 5 in
Supplemental Materials).Discussion
In the context of previous cost-effectiveness evidence, our find-
ings are novel. Pulikottil-Jacob et al11 used a previous economic
model9 to compare 5 commonly used implant combinations in the
United Kingdom. They used NJR data to estimate the risk of revi-
sion and did not account for timing of first and subsequent re-
visions from primary THR. The authors also found that cemented
metal-on-polyethylene implant was cost-effective with increased
Table 3 – Top implant combinations by age and sex, ranked by mean INMB (base case).
Sex Age (y) Top implants Cost (95% CI) QALYs (95% CI) Mean INMB (95% CI)* Probability most
cost-effective*
Men <55 CoP Cem S £2528 (£1588 to £4797) 14.10 (13.84 to 14.35) £1163 (£1147 to £3356) 0.222
MoP Cem S £3284 (£2140 to £4983) 14.08 (13.82 to 14.33) £0 0.002
CoC Uncem S £4226 (£3150 to £6339) 14.08 (13.83 to 14.34) £754 (£2701 to £1111) 0.000
55-64 CoP Cem S £1576 (£1221 to £2374) 10.73 (10.66 to 10.80) £514 (£313 to £1807) 0.477
MoP Cem S £1826 (£1247 to £3144) 10.72 (10.64 to 10.79) £0 0.033
MoP Hyb S £2409 (£1814 to £3567) 10.72 (10.64 to 10.79) £577 (£1102 to £33) 0.000
65-74 MoP Cem S £1300 (£1112 to £1510) 7.99 (7.94 to 8.04) £0 0.399
CoP Cem S £1648 (£1286 to £2423) 7.99 (7.93 to 8.04) £358 (£1385 to £117) 0.054
MoP Hyb S £1941 (£1686 to £2324) 7.98 (7.93 to 8.04) £673 (£1079 to £438) 0.000
75-84 MoP Cem S £986 (£907 to £1071) 5.09 (5.05 to 5.14) £0 0.882
CoP Cem S £1333 (£1151 to £1842) 5.09 (5.04 to 5.14) £370 (£1103 to £115) 0.000
MoP Hyb S £1676 (£1518 to £1954) 5.09 (5.04 to 5.13) £755 (£1087 to £604) 0.000
>85 MoP Cem S £867 (£826 to £916) 2.43 (2.37 to 2.50) £0 0.901
CoP Cem S £1197 (£1064 to £1630) 2.43 (2.37 to 2.50) £365 (£1111 to £133) 0.000
MoP Hyb S £1440 (£1370 to £1562) 2.43 (2.37 to 2.50) £575 (£734 to £475) 0.000
Women <55 CoP Cem S £1822 (£1427 to £2596) 14.48 (14.29 to 14.67) £823 (£10 to £2140) 0.499
MoP Cem S £2374 (£1635 to £3623) 14.47 (14.28 to 14.66) £0 0.006
MoP Hyb S £2749 (£2058 to £3928) 14.47 (14.28 to 14.66) £351 (£1150 to £520) 0.000
55-64 CoP Cem S £1673 (£1324 to £2513) 11.43 (11.36 to 11.49) £104 (£729 to £625) 0.281
MoP Cem S £1692 (£1344 to £2118) 11.42 (11.36 to 11.49) £0 0.085
MoP Hyb S £2033 (£1734 to £2455) 11.43 (11.36 to 11.49) £296 (£582 to £30) 0.001
65-74 MoP Cem S £1210 (£1052 to £1380) 8.66 (8.61 to 8.70) £0 0.838
CoP Cem S £1452 (£1233 to £1982) 8.66 (8.61 to 8.70) £218 (£746 to £14) 0.031
MoP Hyb S £1973 (£1704 to £2361) 8.66 (8.61 to 8.70) £778 (£1103 to £596) 0.000
75-84 MoP Cem S £940 (£877 to £1007) 5.51 (5.47 to 5.55) £0 0.935
CoP Cem S £1319 (£1148 to £1870) 5.51 (5.47 to 5.55) £369 (£879 to £211) 0.000
MoP Hyb S £1594 (£1478 to £1804) 5.51 (5.47 to 5.55) £660 (£831 to £587) 0.000
>85 MoP Cem S £840 (£810 to £874) 2.75 (2.70 to 2.79) £0 0.990
CoP Cem S £1191 (£1067 to £1530) 2.75 (2.71 to 2.79) £344 (£687 to £220) 0.000
MoP Cem L £1433 (£900 to £2200) 2.75 (2.71 to 2.80) £498 (£1219 to £66) 0.002
Cem indicates cemented; CI, confidence interval; CoC, ceramic-on-ceramic; CoP, ceramic-on-polyethylene; Hyb, hybrid; INMB, incremental net
monetary benefit; L, large; MoP, metal-on-polyethylene; QALY, quality-adjusted life-year; RevHyb, reverse hybrid; S, small; Uncem,
uncemented.
* At £20 000 willingness-to-pay threshold.
V A L U E I N H E A L T H 2 2 ( 2 0 1 9 ) 3 0 3 e3 1 2 309age, whereas cemented ceramic-on-polyethylene was favorable
in younger adults, aged 60 years. Clarke et al10 found that
cemented ceramic-on-polyethylene was favorable in young
adults when comparing 5 similar implant combinations with hip
resurfacing in adults aged 40, 50, and 60 years in the United
Kingdom. Although both studies are consistent with our findings,
they were limited in the number of implants compared. They used
only NJR data to estimate the risk of revision and extrapolated
these data to provide longer term estimates. Our study exceeded
these analyses by incorporating reliable long-term estimates of
revision risk from SHAR.We also examined implant head size and
found evidence in favor of small-head implant sizes.
Our results differed from those reported by Pennington
et al15 who found that hybrid prostheses were most likely to be
cost-effective in adults aged 60, 70, and 80 years in the United
Kingdom, with the exception of women aged 80 years for whom
cemented prostheses were cost-effective. Although this
model15 used NJR and Hospital Episode Statistics data to esti-
mate the hazard of first revision, it did not distinguish between
bearing surface combination or implant head size. Pennington
et al15 also used prosthesis-specific utility estimates, which
returned higher utility gains for hybrid prostheses than did
cemented and uncemented prostheses. We used the same
utility estimates for primary THR, irrespective of the implant
combination, because we did not consider implant type to affectquality of life beyond the first 6 months of surgery, as evidenced
elsewhere.30
Previous models for the Italian population also focused on
identifying the most cost-effective fixation technique. Di Tanna
et al13 showed that uncemented implants were cost-effective
compared with hybrid prostheses, whereas Marinelli et al14
found that cemented prostheses were less costly than unce-
mented prostheses, but also less effective. These studies were
limited by their use of regional registry data in Italy, which had
fewer than 10 years follow-up on less than 50 000 patients. We
found that cemented prostheses were at least as effective as
uncemented prostheses, and it is their much lower price that
renders them cost-effective options. In US35 and Canadian36
studies, THR implants were compared with hip resurfacing, with
conflicting results. We did not consider hip resurfacing in our
analysis because the method is declining in clinical use in the
United Kingdom (now <1% of hip replacements)2 and is not rec-
ommended in women and men who do not have very large native
femoral heads.37
We acknowledge that there are limitations associated with
this work. We used a piecewise constant hazard model to esti-
mate the hazard of revision, which was often uncertain. We
considered alternative parametric functions including a Weibull
model and structured model that combined information on
bearing surface, fixation technique, and head size. Ultimately, the
Table 4 – Top implant combinations by age and sex, ranked by mean INMB (sensitivity analysis).
Sex Age (y) Top
implants
Base-case
INMB
ranking
Cost (95% CI) QALYs (95% CI) Mean INMB (95% CI)* Probability most
cost-effective*
Men <55 CoP Cem S 1 £1487 (£548 to £3661) 14.10 (13.85 to 14.35) £1419 (£877 to £3542) 0.039
CoC Uncem S 3 £1966 (£893 to £4111) 14.08 (13.83 to 14.34) £718 (£1273 to £2570) 0.000
MoP Cem S 2 £2505 (£1358 to £4203) 14.08 (13.83 to 14.33) £0 0.000
55-64y CoP Cem S 1 £536 (£185 to £1349) 10.73 (10.66 to 10.8) £794 (£53 to £2058) 0.142
CoC Hyb S 4 £792 (£213 to £2422) 10.73 (10.65 to 10.80) £445 (£1547 to £1853) 0.066
CoP Uncem S 8 £1047 (£453 to £2149) 10.72 (10.64 to 10.79) £64 (£756 to £886) 0.000
65-74 MoP Cem S 1 £543 (£352 to £749) 7.99 (7.94 to 8.04) £0 0.000
CoP Cem S 2 £609 (£249 to £1372) 7.99 (7.93 to 8.04) £75 (£1074 to £399) 0.009
CoC Uncem S 6 £603 (£328 to £1159) 7.99 (7.93 to 8.03) £75 (£778 to £245) 0.000
75-84 MoP Cem S 1 £229 (£151 to £313) 5.09 (5.05 to 5.14) £0 0.031
CoP Cem S 2 £294 (£110 to £807) 5.09 (5.04 to 5.14) £88 (£811 to £164) 0.112
MoP Hyb S 3 £360 (£203 to £632) 5.09 (5.04 to 5.13) £196 (£535 to £42) 0.000
>85 MoP Cem S 1 £111 (£69 to £161) 2.43 (2.37 to 2.5) £0 0.035
MoP Hyb S 3 £127 (£55 to £250) 2.43 (2.37 to 2.5) £19 (£187 to £84) 0.051
CoP Cem S 2 £159 (£27 to £610) 2.43 (2.36 to 2.5) £83 (£881 to £148) 0.115
Women <55z CoP Cem S 1 £785 (£381 to £1584) 14.48 (14.30 to 14.67) £1109 (£293 to £2457) 0.127
CoC Hyb S 4 £1269 (£371 to £3914) 14.48 (14.29 to 14.67) £576 (£2201 to £2056) 0.107
CoP Uncem L 7 £1478 (£459 to £3835) 14.48 (14.28 to 14.66) £256 (£2145 to £1690) 0.038
55-64x CoC Hyb S 4 £561 (£209 to £1962) 11.43 (11.36 to 11.49) £478 (£1006 to £1131) 0.175
CoP Cem S 1 £635 (£285 to £1481) 11.43 (11.36 to 11.49) £381 (£449 to £896) 0.036
MoP Hyb S 3 £715 (£416 to £1139) 11.43 (11.36 to 11.49) £262 (£25 to £590) 0.001
65-74 CoP Cem S 2 £413 (£194 to £926) 8.66 (8.61 to 8.70) £65 (£438 to £292) 0.086
MoP Cem S 1 £453 (£291 to £621) 8.66 (8.61 to 8.70) £0 0.000
CoP Uncem S 6 £522 (£301 to £886) 8.66 (8.61 to 8.70) £96 (£414 to £76) 0.000
75-84 MoP Cem S 1 £184 (£122 to £251) 5.51 (5.47 to 5.55) £0 0.058
CoP Cem S 2 £276 (£110 to £798) 5.51 (5.47 to 5.55) £82 (£567 to £74) 0.049
MoP Hyb S 3 £279 (£163 to £491) 5.51 (5.47 to 5.55) £100 (£274 to £27) 0.000
>85 MoP Cem S 1 £85 (£54 to £119) 2.75 (2.71 to 2.79) £0 0.184
MoP Hyb S 5 £115 (£63 to £191) 2.75 (2.71 to 2.79) £35 (£98 to £8) 0.015
CoP Cem S 2 £156 (£28 to £513) 2.75 (2.71 to 2.79) £65 (£422 to £63) 0.126
Cem indicates cemented; CI, confidence interval; CoC, ceramic-on-ceramic; CoP, ceramic-on-polyethylene; Hyb, hybrid; INMB, incremental net
monetary benefit; L, large; MoP, metal-on-polyethylene; QALY, quality-adjusted life-year; RevHyb, reverse hybrid; S, small; Uncem,
uncemented.
* At £20 000 willingness-to-pay threshold.
y Men 55-64 y: reference implant cost, £1067 (£481-£2407); QALYs, 10.72 (10.64-10.79).
z Women <55 y: reference implant cost, £1621 (£866-£2864); QALYs, 14.47 (14.28-14.66).
x Women 55-64 y: reference implant cost, £933 (£582-£1369); QALYs, 11.42 (11.36-11.49).
V A L U E I N H E A L T H 2 2 ( 2 0 1 9 ) 3 0 3 e3 1 2310piecewise constant hazard model was either the best fit for the
data or yielded a similar level of precision of revision risk. Estab-
lished in 2002, with data collection commencing 2003/2004, the
NJR had limited follow-up data to predict lifetime hazards of
revision, particularly for newer implants. SHAR collects informa-
tion on polyethylene implants, whereas the NJR does not classify
polyethylene types. It is possible that different types of poly-
ethylene, for example, newer highly cross-linked (HCL) poly-
ethylene, would lead to different implant survival profiles. In
previous work, we performed a systematic review and synthesis
of RCT evidence, which included comparisons between HCL and
non-HCL implants, and did not find an effect for newer poly-
ethylene types.22 In the absence of reliable or precise estimates
from RCTs, we were required to rely on joint registries. Such real-
world evidence22 has the advantage of large sample sizes, external
validity, and longer term follow-up. A general difficulty with using
observational data is selection bias. To attempt to mitigate bias
and obtain as robust estimates as possible, we stratified our an-
alyses by known predictors of revision risk, such as implant
combination, patients’ age and sex, and time from first revision.
Nevertheless, it is possible that surgeons select patients to receivedifferent implant combinations on the basis of other factors, such
as their surgical training or skills, preferences for implant types or
bands, patients’ bone anatomy or comorbidities, or hospital pro-
curement decisions and costs. These factors are not routinely
captured in joint registries, and we were therefore unable to
adjust for these factors in our analyses. Although SHAR provided
long-term evidence on implant survival, a limitation associated
with using SHAR data was that 90% of prostheses were fixed with
cement,38 leaving little information on hybrid/reverse hybrid and
uncemented prostheses. As would be expected, this uncertainty
propagated into the cost-effectiveness results. We estimated the
risk of first revision stratified by implant type, patients’ age and
sex, and time from primary surgery. There were insufficient data
in both registries to stratify the risk of subsequent revisions by all
these factors, and it was necessary to assume the same risk across
all implants, ages, and sexes for subsequent revisions. Limited
availability of data for more recent or less common implant types
led to imprecise hazard ratios for some implant combinations (as
presented in Table 2). These account for the uncertainty in our
results, particularly for younger patients. Although we aimed to
provide a comprehensive analysis of all possible implant
V A L U E I N H E A L T H 2 2 ( 2 0 1 9 ) 3 0 3 e3 1 2 311combinations using the most up-to-date data available, there
might not be enough evidence yet to fully assess these implant
combinations. Future research should assess the longer term
benefits associated with newer implant combinations. Implant
costs were assumed fixed, but likely vary between healthcare
providers because of locally negotiated contracts with manufac-
turers. Finally, although we assumed the same utility scores
across implant combinations, as in the studies by Pulikottil-Jacob
et al11 and Clarke et al,10 it is possible some differences exist.
Pennington et al,15 using observational PROMs data, found a
modest association between quality-of-life scores at 6 months
postsurgery and fixation techniques. Nevertheless, when
comparing across fixation techniques with optimal and subopti-
mal bearing surface combinations and femoral head sizes,
Jameson et al30 found no difference in utility scores at 6 months
postsurgery using the same data set. Their analysis more closely
resembled ours (i.e., by comparing bearing surface combination,
fixation technique, and head size), and so we assumed no differ-
ence in utility scores by implant types and instead stratified utility
estimates by age and sex. Further research is needed to determine
whether utility scores differ by implant combinations because
potential differences may have an impact on cost-effectiveness
findings.
Our findings suggest that for older patients, the small-head
cemented metal-on-polyethylene implant is the most likely cost-
effective choice in primary THR. This is the cheapest and most
common implant combination used in the United Kingdom, used
in 30% of patients with THR since 2003/2004.2 Metal-on-
polyethylene implants also remain the most commonly used
bearing surface material in Sweden, Norway, Australia, and the
United States, although in some countries, such as the United
States and Australia, they are more commonly fixed without
cement.3,4,39 Ceramic and uncemented or hybrid combinations are
increasingly used in younger adults worldwide.2-4 Our findings
indicate that cemented hip implants would be the cost-effective
fixation option, regardless of bearing size and surface combination.
Our study can influence clinical practice and commissioning of
services. We, however, highlight the need for rigorous RCTs with
long-term follow-up before costly new implants are widely
adopted in practice.Conclusions
We found that the older the patient group, themore likely that the
small-head cemented metal-on-polyethylene implant is the cost-
effective choice. This implant has more than 80% probability of
being the most cost-effective choice for men and women aged 65
years and older. The small-head cemented metal-on-
polyethylene implant is the cheapest implant combination
available, at about £750, and displays some of the lowest risks of
revision surgery for older men and women. For patients younger
than 65 years, the small-head cemented ceramic-on-polyethylene
implant is cost-effective, but these results are more uncertain,
mainly because of more imprecise estimates of revision risks. The
key drivers of the analysis were revision costs and revision risks.
In younger adults, the lower risk of revision after small-head
cemented ceramic-on-polyethylene hip replacements led to
lower average lifetime costs and higher QALY gains compared
with the most commonly used implant. Similarly, in older adults,
small-head cemented metal-on-polyethylene hip replacements
consistently displayed lower lifetime costs and the same or higher
QALY gains because of lower implant costs and more favorable
revision rates.
Our findings are based on the best available current evidence.
We analyzed more than 1 million individual-patient records
across 2 national joint registries in the United Kingdom andSweden. We developed a tunnel-state Markovmodel, informed by
a team of hip surgeons, patients, and previous economic models.
Our model’s structure was flexible enough to capture the impact
of age, sex, and time since initial THR on the hazards and hazard
ratios of revision, as well as the clinical reality that patients who
were revised soon after primary THR were at an increased risk of
having second and subsequent revisions.Acknowledgments
This article summarizes findings from the Hip Implant Prostheses
Study (HIPS). We are grateful to its steering group members: Keith
Abrams (University of Leicester), Mark Wilkinson (University of
Sheffield and NJR Scientific Committee), and Mark Pennington
(Kings College London) for methodological advice, and lay mem-
bers David Peacock and Michael Nicholson for patient views. We
thank the 2 patient and public involvement groups at the
Musculoskeletal Research UnitdPEP-R and PPI INFORMdfor their
views in PPI meetings and James Berstock, Flossie Carpenter, and
Michael Whitehouse for surgeons’ views in stakeholders’ meet-
ings. We thank Mark Branton at North Bristol NHS Trust Finance
Department for providing implant procurement prices. H. H. Z.
Thom was supported by the Medical Research Council ConDuCT-
II Hub for Trials Methodology Research (grant no. MR/K025643/1).
We thank the patients and staff of all the hospitals in England,
Wales, and Northern Ireland who have contributed data to the
NJR. We are grateful to the Healthcare Quality Improvement
Partnership, the NJR Research Subcommittee, and staff at the NJR
center for facilitating this work. We have conformed to NJR’s
standard protocol for data access and publication. The views
expressed represent our views and do not necessarily reflect those
of the NJR Steering Committee or the Health Quality Improvement
Partnership, which do not vouch for how the information is
presented.
Source of financial support: This article summarizes inde-
pendent research funded by the National Institute for Health
Research's Research for Patient Benefit Programme (grant no. PB-
PG-0613-31032).Supplemental Materials
Supplementary data associated with this article can be found in
the online version at https://doi.org/10.1016/j.jval.2018.08.013.R E F E R E N C E S
1. Learmonth ID, Young C, Rorabeck C. The operation of the century: total
hip replacement. Lancet 2007;370(9597):1508e19.
2. National Joint Registry. 14th Annual Report. Bristol, UK: National Joint
Registry for England, Wales, Northern Ireland and the Isle of Man; 2017.
3. Karrholm J, Lindahl H, Malchau H, Mohaddes M, Rogmark C, Rolfson O.
Swedish Hip Arthroplasty Register: Annual Report 2015. Gothenburg,
Sweden: Swedish Hip Arthroplasty Register; 2016.
4. Australian Orthopedic Association. Hip, Knee and Shoulder
Arthroplasty Annual Report 2016. Sydney, Australia: Australian
Orthopedic Association National Joint Replacement Registry; 2017.
5. Maradit Kremers H, Larson DR, Crowson CS, et al. Prevalence of total hip
and knee replacement in the United States. J Bone Joint Surg Am
2015;97(17):1386e97.
6. Berry DJ, Harmsen WS, Cabanela ME, Morrey BF. Twenty-five-year
survivorship of two thousand consecutive primary Charnley total hip
replacements: factors affecting survivorship of acetabular and femoral
components. J Bone Joint Surg Am 2002;84-a(2):171e7.
7. Smith AJ, Dieppe P, Vernon K, Porter M, Blom AW. Failure rates of
stemmed metal-on-metal hip replacements: analysis of data from the
V A L U E I N H E A L T H 2 2 ( 2 0 1 9 ) 3 0 3 e3 1 2312National Joint Registry of England and Wales. Lancet
2012;379(9822):1199e204.
8. Norwegian Arthroplasty Register. Norwegian National Advisory Unit on
Arthroplasty and Hip Fractures: 2016 Annual Report. Bergen, Norway:
Norwegian Arthroplasty Register; 2016.
9. Briggs A, Sculpher MJ, Dawson J, Fitzpatrick R, Murray D, Malchau H.
Modelling the Cost-Effectiveness of Primary Hip Replacement: How
Cost-Effective Is the Spectron Compared to the Charnley Prosthesis?.
York, UK: University of York; 2003.
10. Clarke A, Pulikottil-Jacob R, Grove A, Freeman K, Mistry H,
Tsertsvadze A. Total hip replacement and surface replacement for the
treatment of pain and disability resulting from end-stage arthritis of the
hip (review of technology appraisal guidance 2 and 44): systematic
review and economic evaluation. Health Technol Assess
2015;19(10):1e668. vii-viii.
11. Pulikottil-Jacob R, Connock M, Kandala NB, et al. Cost effectiveness of
total hip arthroplasty in osteoarthritis: comparison of devices with
differing bearing surfaces and modes of fixation. Bone Joint J 2015;97-
b(4):449e57.
12. Fitzpatrick R, Shortall E, Sculpher M, et al. Primary total hip replacement
surgery: a systematic review of outcomes and modelling of cost-
effectiveness associated with different prostheses. Health Technol
Assess 1998;2(20):1e64.
13. Di Tanna GL, Ferro S, Cipriani F, et al. Modeling the cost-effectiveness
for cement-less and hybrid prosthesis in total hip replacement in Emilia
Romagna, Italy. J Surg Res 2011;169(2):227e33.
14. Marinelli M, Soccetti A, Panfoli N, de Palma L. Cost-effectiveness of
cemented versus cementless total hip arthroplasty: a Markov decision
analysis based on implant cost. J Orthop Traumatol 2008;9(1):23e8.
15. Pennington M, Grieve R, Sekhon JS, Gregg P, Black N, van der Meulen JH.
Cemented, cementless, and hybrid prostheses for total hip replacement:
cost effectiveness analysis. BMJ 2013;346:f1026.
16. Epinette JA, Lafuma A, Robert J, Doz M. Cost-effectiveness model
comparing dual-mobility to fixed-bearing designs for total hip
replacement in France. Orthop Traumatol Surg Res 2016;102(2):143e8.
17. Slover J, Hoffman MV, Malchau H, Tosteson AN, Koval KJ. A cost-
effectiveness analysis of the arthroplasty options for displaced femoral
neck fractures in the active, healthy, elderly population. J Arthroplasty
2009;24(6):854e60.
18. Marques EMR, Humphriss R, Welton NJ, et al. The choice between hip
prosthetic bearing surfaces in total hip replacement: a protocol for a
systematic review and network meta-analysis. Syst Rev 2016;5(1):1e8.
19. Bozic KJ, Morshed S, Silverstein MD, Rubash HE, Kahn JG. Use of cost-
effectiveness analysis to evaluate new technologies in orthopaedics: the
case of alternative bearing surfaces in total hip arthroplasty. J Bone Joint
Surg Am 2006;88(4):706e14.
20. Annual reports. National Joint Registry. http://www.njrcentre.org.uk/
njrcentre/Reports,PublicationsandMinutes/Annualreports/tabid/86/
Default.aspx. Accessed October 6, 2017.
21. Hunt LP, Whitehouse MR, Beswick AD, Porter ML, Howard P, Blom AW.
Implications of introducing new technology: comparative survivorship
modeling of metal-on-metal hip replacements and contemporary
alternatives in the National Joint Registry. J Bone Joint Surg Am
2018;100(3):189e96.
22. Lopez-Lopez JA, Humphriss RL, Beswick AD, et al. Choice of implant
combinations in total hip replacement: systematic review and network
meta-analysis. BMJ 2017;359:j4651. https://doi.org/10.1136/bmj.j4651.
23. National life tables, 2013-2015. Office for National Statistics. https://
www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdom
referencetables. Accessed October 6, 2017.
24. Hunt LP, Ben-Shlomo Y, Clark EM, et al. 90-day mortality after 409,096
total hip replacements for osteoarthritis, from the National Joint
Registry for England and Wales: a retrospective analysis. Lancet
2013;382(9898):1097e104.
25. Briggs T. Raising transparency of pricing for total hip and total knee
replacements: a national pilot on value for money for the NHS in
orthopaedic procurement. British Orthopaedic Association, http://www.
boa.ac.uk/latest-news/raising-transparency-of-pricing-for-total-hip-and-
total-knee-replacements/. Accessed August 31, 2017.
26. Department of Health. Department of Health Reference Costs: 2015-
2016. London: National Health Service; 2016.
27. Edlin R, Tubeuf S, Achten J, Parsons N, Costa M. Cost-effectiveness
of total hip arthroplasty versus resurfacing arthroplasty:
economic evaluation alongside a clinical trial. BMJ Open
2012;2(5):e001162.
28. Curtis L, Burns A. Unit Costs of Health and Social Care 2015. Kent, UK:
Social Services Research Unit, University of Kent; 2016.
29. Health and Social Care Information Centre. Patient Reported Outcome
Measures (PROMs). 2013. http://www.hscic.gov.uk/proms. Accessed
November 2017.
30. Jameson SS, Mason J, Baker PN, Gregg PJ, Deehan DJ, Reed MR. Implant
optimisation for primary hip replacement in patients over 60 years
with osteoarthritis: a cohort study of clinical outcomes and implant
costs using data from England and Wales. PLoS One
2015;10(11):e0140309.
31. National Institute for Health and Care Excellence. Guide to the Methods
of Technology Appraisal 2013. London: National Institute for Health and
Care Excellence; 2013.
32. Microsoft Excel. [computer program]. Redmond, WA: Microsoft Corp;
2016. 2016.
33. Marques EM, Blom AW, Lenguerrand E, Wylde V, Noble SM. Local
anaesthetic wound infiltration in addition to standard anaesthetic
regimen in total hip and knee replacement: long-term cost-
effectiveness analyses alongside the APEX randomised controlled trials.
BMC Med 2015;13(1):151.
34. Sentuerk U, von Roth P, Perka C. Ceramic on ceramic arthroplasty of the
hip: new materials confirm appropriate use in young patients. Bone
Joint J 2016;98-b(1 suppl A):14e7.
35. Bozic KJ, Pui CM, Ludeman MJ, Vail TP, Silverstein MD. Do the
potential benefits of metal-on-metal hip resurfacing justify the
increased cost and risk of complications? Clin Orthop Relat Res
2010;468(9):2301e12.
36. Heintzbergen S, Kulin NA, Ijzerman MJ, et al. Cost-utility of metal-on-
metal hip resurfacing compared to conventional total hip replacement
in young active patients with osteoarthritis. Value Health
2013;16(6):942e52.
37. Smith AJ, Dieppe P, Howard PW, Blom AW. Failure rates of
metal-on-metal hip resurfacings: analysis of data from the
National Joint Registry for England and Wales. Lancet
2012;380(9855):1759e66.
38. Hailer NP, Garellick G, K€arrholm J. Uncemented and cemented
primary total hip arthroplasty in the Swedish Hip Arthroplasty
Register: evaluation of 170,413 operations. Acta Orthop
2010;81(1):34e41.
39. Kurtz SM. UHMWPE Biomaterials Handbook: Ultra High Molecular
Weight Polyethylene in Total Joint Replacement and Medical Devices.
London: Academic Press; 2009.
